Nextech Invest Ltd.

CIK 1595430 · View on SEC EDGAR ↗

Portfolio value
$2.1B
#1,466 of 9,443 by 13F value · top 15.5%
Positions
15
As of
June 30, 2026

Portfolio value QoQ: +47.3% 13F does not disclose cash

Top 10 holdings weight
98.65%
Top 25 holdings weight
100.00%
Positions above 1%
8
Effective number of positions
2.1

Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)

Turnover Q2 2026: 9.45% Est. buys $166,098,145 · sells $206,519,667

Median holding: 5.0 quarters Tracked Q1 2025–Q2 2026 · 65.2% still held

New positions
2
Increased
2
Decreased
2
Closed
4
On this page

Performance vs S&P 500

Tracked Q1 2025–Q2 2026
+367.0%
S&P 500 total return (same window)
+37.0%
Excess return
+330.0%

Annualized: +243.4% · S&P 500: +28.7%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 99.1% · Options excluded: 0.0%

Sector breakdown

Healthcare
93.7%
Other/Unmapped
6.3%

Full portfolio 15 positions

Type Streak 8Q trend
RVMD Revolution Medicines, Inc. - Common Stock $1,423,531,573 68.01% 7,601,087 $684,325,862
Unknown issuer (CUSIP: 698955101) $127,631,127 6.10% 4,663,176 Up ×1
RLAY Relay Therapeutics, Inc. - Common Stock $126,788,427 6.06% 6,776,506 $71,799,692 Up ×3
TYRA Tyra Biosciences, Inc. - Common Stock $113,501,505 5.42% 3,553,585 $-41,837,971 Down ×1
ALMS Alumis Inc. - Common Stock $99,643,684 4.76% 3,540,998 $21,635,498
ORIC Oric Pharmaceuticals, Inc. - Common Stock $77,571,359 3.71% 7,162,637 $-13,179,252
KYMR Kymera Therapeutics, Inc. - Common Stock $31,981,004 1.53% 278,896 $8,751,756
ZYME Zymeworks Inc. - Common Stock $29,118,548 1.39% 1,113,946 $1,225,340
GLUE Monte Rosa Therapeutics, Inc. - Common Stock $18,419,903 0.88% 761,153 $13,415,204 Up ×2
CTMX CytomX Therapeutics, Inc. - Common Stock $16,687,245 0.80% 4,449,932 $-4,227,435
SLN Silence Therapeutics Plc - American Depository Share $10,457,352 0.50% 952,400 $5,438,204
CRVS Corvus Pharmaceuticals, Inc. - Common Stock $6,723,000 0.32% 450,000 $139,500
CNTX Context Therapeutics Inc. - Common Stock $4,109,581 0.20% 7,419,355 $-15,329,129
Unknown issuer (CUSIP: 29286X101) $4,022,151 0.19% 2,324,943 Up ×1
ARVN Arvinas, Inc. - Common Stock $2,964,285 0.14% 356,713 $-2,753,291 Down ×1

Conviction holdings

Positions increased for 3+ consecutive quarters.

Share counts are as reported in 13F filings (not split-adjusted)

Security Value % of portfolio Streak
RLAY $126,788,427 6.06% up ×3

Biggest new bets

New positions opened this quarter, largest first.

Security Value Shares % of portfolio
Unknown issuer (CUSIP: 698955101) $127,631,127 4,663,176 6.10%
Unknown issuer (CUSIP: 29286X101) $4,022,151 2,324,943 0.19%

Top movers (QoQ)

Security Action Shares Δ Value Δ
RVMD Price move only +0 +$684.3M
RLAY Bought more +1.2M +$71.8M
TYRA Trimmed -502K -$41.8M
ALMS Price move only +0 +$21.6M
CNTX Price move only +0 -$15.3M
GLUE Bought more +457K +$13.4M
ORIC Price move only +0 -$13.2M
KYMR Price move only +0 +$8.8M
SLN Price move only +0 +$5.4M
CTMX Price move only +0 -$4.2M

Exited positions

Includes corporate events (mergers, delistings) — not all exits are sells

Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.

SecurityQuarter Shares before Value before Price since exit
TNGX June 30, 2026 7,266,081 $152,006,415 -16.6%
CGEM June 30, 2026 1,141,145 $16,215,670 19.1%
ENGN June 30, 2026 2,324,943 $15,832,862 1.2%
MRSN March 31, 2026 482,689 $13,964,193 No longer tracked
CRGX Sept. 30, 2025 2,642,502 $10,887,108 No longer tracked
SPRY June 30, 2026 610,703 $4,903,945 -18.4%
BOLD Dec. 31, 2025 1,228,069 $1,510,525 143.0%